GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyclo Therapeutics Inc (NAS:CYTH) » Definitions » Operating Margin %

Cyclo Therapeutics (Cyclo Therapeutics) Operating Margin % : -1,814.47% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Cyclo Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Cyclo Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-5.64 Mil. Cyclo Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.31 Mil. Therefore, Cyclo Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was -1,814.47%.

Warning Sign:

Cyclo Therapeutics Inc operating margin has been in a 5-year decline. The average rate of decline per year is -28%.

The historical rank and industry rank for Cyclo Therapeutics's Operating Margin % or its related term are showing as below:

CYTH' s Operating Margin % Range Over the Past 10 Years
Min: -1865.12   Med: -577.42   Max: -35.86
Current: -1865.12


CYTH's Operating Margin % is ranked worse than
96.66% of 1018 companies
in the Drug Manufacturers industry
Industry Median: 6.075 vs CYTH: -1865.12

Cyclo Therapeutics's 5-Year Average Operating Margin % Growth Rate was -28.00% per year.

Cyclo Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-5.64 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-20.05 Mil.


Cyclo Therapeutics Operating Margin % Historical Data

The historical data trend for Cyclo Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclo Therapeutics Operating Margin % Chart

Cyclo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -733.96 -992.25 -899.62 -1,134.59 -1,863.38

Cyclo Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,659.36 -3,294.08 -3,959.83 -963.03 -1,814.47

Competitive Comparison of Cyclo Therapeutics's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Cyclo Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclo Therapeutics's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyclo Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Cyclo Therapeutics's Operating Margin % falls into.



Cyclo Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Cyclo Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-20.05 / 1.076
=-1,863.38 %

Cyclo Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-5.643 / 0.311
=-1,814.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyclo Therapeutics  (NAS:CYTH) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Cyclo Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Cyclo Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclo Therapeutics (Cyclo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6714 North West 16th Street, Suite B, Gainesville, FL, USA, 32653
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex.
Executives
Vivien Wong director 6C CHATEAUX CIRCLE, SCARSDALE NY 10583
Rafael Holdings, Inc. 10 percent owner 520 BROAD STREET, NEWARK NJ 07120
William Conkling director C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Jeffrey Tate director, officer: Chief Executive Officer C/O CTD HOLDINGS, INC., 27317 NW 78TH AVENUE, HIGH SPRINGS FL 32643
Francis Patrick Ostronic director 932 HUNGERFORD DRIVE, SUITE 28A, ROCKVILLE MD 20850
Markus Sieger director BEUTSTWEG 12, CH-8032, ZURICH V8 000000000
N Scott Fine director 600 3RD AVE, NEW YORK NY 10016
Sharon Hemond Hrynkow officer: SVP for Medical Affairs 4816 KING SOLOMON DRIVE, ANNADALE VA 22003
Lise Lund Kjems officer: Chief Medical Officer 91 ROLLINGWOOD LN., CONCORD MA 01742
Joshua M Fine officer: Chief Financial Officer 21 HEMMELSKAMP ROAD, WILTON CT 06897
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Michael Eric Lisjak officer: Chief Regulatory Officer 12 ROOSEVELT AVENUE, OLD GREENWICH CT 06870
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
L.p. Novit, 10 percent owner 966 HUNGERFORD DRIVE, ROCKVILLE MD 20850